Here are three quick notes:
1. Firms covering the shares have a one-year price target of $87.88.
2. On Dec. 1, 2016, Robert Baird rated the shares a “buy.”
3. During the second quarter last year, LS Investment Advisors increased its position in AmSurg by 68.7 percent.
More articles on surgery centers:
5 statistics on ENT net revenue per case in ASCs
Mount Sinai establishes Eye and Vision Research Institute: 4 key notes
Nobilis Health Corp. to acquire Hamilton Vein Center for $13.3M — 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.